NAGE
Niagen Bioscience
PE ratio, current and historical analysis
- Stocks
- Healthcare
- NASDAQ: NAGE
- PE Ratio
The current P/E ratio for Niagen Bioscience stock as of Sep 23, 2026 is 15.0. This is calculated based on the TTM EPS of $0.2 and the stock price of $3 per share. The PE ratio has decreased by 39% from its last 4 quarters average of 24.5.
NAGE PE ratio history
The average historical PE ratio of Niagen Bioscience for the last two years is 76.5. The current price-to-earnings ratio of 15.0 is 80% less than the historical average. Analyzing the last two years, NAGE's PE ratio reached its highest point in the Sep 2024 quarter at 365, when the price was $3.65 and the EPS was $0.01. The lowest point was recorded in the Jun 2026 quarter, when it reached 15.95 with a price of $3.19 and an EPS of $0.2.
Niagen Bioscience PE ratio by year
Maximum annual decrease: -40.06% in 2025
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2025 | 28.91 | -40.06% | $6.36 | $0.22 |
| 2024 | 48.23 | N/A | $5.31 | $0.11 |
| 2023 | N/A | N/A | $1.43 | -$0.07 |
| 2022 | N/A | N/A | $1.68 | -$0.24 |
| 2021 | N/A | N/A | $3.74 | -$0.4 |
| 2020 | N/A | N/A | $4.8 | -$0.33 |
| 2019 | N/A | N/A | $4.31 | -$0.56 |
| 2018 | N/A | N/A | $3.43 | -$0.61 |
| 2017 | N/A | N/A | $5.88 | -$0.26 |
| 2016 | N/A | N/A | $3.31 | -$0.08 |
| 2016 | N/A | N/A | $3.66 | -$0.08 |
| 2015 | N/A | N/A | $2.7 | -$0.15 |
| 2013 | N/A | N/A | $4.8 | -$0.12 |
| 2012 | N/A | N/A | $1.68 | -$0.39 |
| 2011 | N/A | N/A | $1.65 | -$0.36 |
Niagen Bioscience PE ratio by quarter (TTM)
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Jun 2026 | 15.95 | -13.22% | $3.19 | $0.2 |
| Mar 2026 | 18.38 | -36.42% | $4.41 | $0.24 |
| Dec 2025 | 28.91 | -16.35% | $6.36 | $0.22 |
| Sep 2025 | 34.56 | -44.84% | $9.33 | $0.27 |
| Jun 2025 | 62.65 | 63.45% | $14.41 | $0.23 |
| Mar 2025 | 38.33 | -20.53% | $6.9 | $0.18 |
| Dec 2024 | 48.23 | -86.79% | $5.31 | $0.11 |
| Sep 2024 | 365 | N/A | $3.65 | $0.01 |
| Jun 2024 | N/A | N/A | $2.73 | -$0.02 |
| Mar 2024 | N/A | N/A | $3.48 | -$0.05 |
| Dec 2023 | N/A | N/A | $1.43 | -$0.07 |
| Sep 2023 | N/A | N/A | $1.46 | -$0.09 |
| Jun 2023 | N/A | N/A | $1.57 | -$0.09 |
| Mar 2023 | N/A | N/A | $1.53 | -$0.15 |
| Dec 2022 | N/A | N/A | $1.68 | -$0.24 |
NAGE Price vs fair value
NAGE average PE ratio chart
What this chart measures
The Historical Valuation Regime chart shows where the stock's current valuation sits relative to its own historical valuation range over the selected lookback period.
This is a history-relative tool, not a market-relative percentile. It does not compare the stock to other companies. Instead, it compares each historical valuation reading to the stock's own past readings.
Percentile logic
The threshold lines are calculated them from the stock's real historical values using percentile interpolation. That is why some colored bands are narrow while others are wide: the band widths reflect how the stock actually traded through time.
Regime map
| Historical percentile | Regime | Chart meaning |
|---|---|---|
| 0-10 | Historically Low | Deep cheap zone |
| >10-25 | Below Average | Cheap relative to history |
| >25-75 | Average | Within the normal historical range |
| >75-90 | Above Average | Expensive relative to history |
| >90-100 | Historically High | Extreme or stretched valuation |
How to read each part
| Chart element | What it tells you |
|---|---|
| Main line | The actual historical valuation values over time for the selected metric. |
| Dashed horizontal lines | The stock's computed P10, P25, Median, P75, and P90 thresholds for the selected period. |
| Colored bands | The historical valuation zones between those thresholds. |
| Metric boxes | Current ratio, historical median, current percentile, and current regime. |
| Timeline strip | A condensed regime history showing how the stock moved between cheap, fair, and expensive states across each observation. |
Important metric definitions
Current Percentile is the percentile rank of the latest valid historical observation within the selected lookback range.
Current Regime is assigned directly from the latest observation's percentile bucket using the fixed 10 / 25 / 75 / 90 cutoffs shown above.
How to use it well
This chart is most useful for answering a narrow question: Is this stock trading high, low, or normal relative to its own history? It works best alongside growth, profitability, and forward-looking business analysis, because a stock can deserve a higher or lower regime if its business quality has changed.
Currently, NAGE's PE ratio is under its 3, 5 and 10-year averages.
PE comparison
With a price to earnings (P/E) of 15, NAGE stands higher than the industry average but lower than the Healthcare sector average. Looking at the Healthcare sector average of 23.69, Niagen Bioscience's price to earnings (P/E) is 37% lower.
NAGE PE vs peers
Frequently asked questions
What is Niagen Bioscience's PE ratio?
NAGE stock has a price to earnings ratio of 15 as of Sep 23, 2026.
What is the 3-year average PE ratio for Niagen Bioscience (NAGE)?
The 3-year average PE ratio for NAGE stock is 76.5.
What is the 5-year average PE ratio for Niagen Bioscience (NAGE)?
The 5-year average PE ratio for NAGE stock is 76.5.
What is the highest PE ratio for NAGE?
Over the last two years, the quarterly PE ratio reached its highest level at 365 in the Sep 2024 quarter.
How does the current PE ratio for NAGE compare to its historical average?
The current PE ratio of NAGE is 80% lower than the 2-year historical average.
How is NAGE's PE ratio calculated (Niagen Bioscience PE ratio formula)?
The P/E ratio is calculated by taking the latest stock price and dividing it by the earnings per share(EPS) for the last 12 months. As of today (Sep 23, 2026), Niagen Bioscience's share price is $3. The company's earnings per share for the trailing twelve months (TTM) ending Jun 2026 is $0.2. Therefore, Niagen Bioscience's price to earnings ratio for today is 15. PE RATIO(15) = STOCK PRICE($3) / TTM EPS($0.2)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.